01-04-1999 | Original articles
The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell® technology
Published in: Hematology and Cell Therapy | Issue 2/1999
Login to get access